• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
ZHANG Huazhu,LIU Xiaobo.Research progress of PD⁃1/PD-L1 pathway in melanoma[J].Journal Of Pharmaceutical Research,2021,40(1):40-43,59[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 2727times   Download 2740次 QR Code for this article
Scan with your phone!
PD-1/PD-L1信号通路在黑色素瘤中的研究进展
张华竹,刘晓波
Font:Larger+|Default|Smaller-
(大理大学药学与化学学院,云南 大理 671000)
摘要:
细胞程序性死亡因子1(programmed death-1,PD-1)及其配体1(programmed death- ligand 1,PD- L1)是一对共刺激分子,激活PD-1/PD-L1信号通路可抑制肿瘤特异性T细胞活性,有助于肿瘤细胞逃避免疫监视。而阻断该通路可以激活机体抗肿瘤免疫应答,抑制肿瘤细胞的生长。近年来,针对PD-1/PD-L1通路的免疫疗法在黑色素瘤的治疗中已取得显著效果。本文对PD-1/PD-L1通路在黑色素瘤中的表达调控、PD-1/PD-L1抑制剂在黑色素瘤治疗中的临床研究进行综述,讨论PD-1作为一种新的免疫疗法在临床的应用前景和不良反应。
关键词:  细胞程序性死亡因子1及其配体1信号通路  黑色素瘤  表达调控  临床研究进展
DOI:10.13506/j.cnki.jpr.2021.01.008
基金项目:2017年度云南省地方本科高校(部分)基础研究专项立项项目(No.2017FH001-096);2017年度云南省昆虫生物医药研发重点实验室开放课题(No.EBR&D1706);中国西南药用昆虫及蛛形类资源开发利用协同创新中心2018年度开放课题(No.CIC1801)
Research progress of PD⁃1/PD-L1 pathway in melanoma
ZHANG Huazhu,LIU Xiaobo
(College of Pharmacy and Chemistry,Dali University,Dali 671000,China)
Abstract:
Programmed cell death 1 (PD-1) and its ligand (PD-L1) are a pair of co-stimulatory molecules, PD-1/PD-L1 pathway play an important role in the processes of production,development and escape.Activating the PD-1/PD-L1 pathway can inhibit tumor-specific T cell activity.It has been proved that PD-1 activation contributes to tumor immune escape and PD-1/PD-L1 inhibitors can enhance immune response,inhibit the growth of tumor cells.In recent years,great achievements have been got in melanoma about PD-1/PD-L1 inhibitors. This article reviewed the expression of PD-1/PD-L1 in melanoma and the clinical application of PD-1/PD-L1 inhibitors.Moreover,we further discussed the clinical application prospect and adverse reactions of PD-1/PD-L1 inhibitors.
Key words:  PD-1/PD-L1 signal pathway  Melanoma  Expression regulation  Clinical research progress
Today's Visits:509    Total Visits:2383239
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.